On Friday, CRISPR Therapeutics AG (NASDAQ: CRSP) opened higher 5.13% from the last session, before settling in for the closing price of $43.31. Price fluctuations for CRSP have ranged from $36.52 to $83.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 31550.17% annually for the last half of the decade. Company’s average yearly earnings per share was noted -10.94% at the time writing. With a float of $82.07 million, this company’s outstanding shares have now reached $85.74 million.
In an organization with 393 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -227.47%, operating margin of -1273.97%, and the pretax margin is -990.27%.
CRISPR Therapeutics AG (CRSP) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of CRISPR Therapeutics AG is 4.32%, while institutional ownership is 69.38%. The most recent insider transaction that took place on Feb 26 ’25, was worth 313,948. In this transaction Director of this company bought 7,000 shares at a rate of $44.85, taking the stock ownership to the 7,000 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Chief Executive Officer sold 18,360 for $55.20, making the entire transaction worth $1,013,564. This insider now owns 171,613 shares in total.
CRISPR Therapeutics AG (CRSP) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.94% per share during the next fiscal year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Check out the current performance indicators for CRISPR Therapeutics AG (CRSP). In the past quarter, the stock posted a quick ratio of 22.07. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 104.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.36, a number that is poised to hit -1.23 in the next quarter and is forecasted to reach -4.05 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
Let’s dig in a bit further. During the last 5-days, its volume was 1.64 million. That was inferior than the volume of 2.27 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 49.81%. Additionally, its Average True Range was 2.92.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 39.96%, which indicates a significant increase from 32.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.38% in the past 14 days, which was lower than the 57.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $42.62, while its 200-day Moving Average is $48.91. However, in the short run, CRISPR Therapeutics AG’s stock first resistance to watch stands at $46.72. Second resistance stands at $47.91. The third major resistance level sits at $50.03. If the price goes on to break the first support level at $43.41, it is likely to go to the next support level at $41.29. Assuming the price breaks the second support level, the third support level stands at $40.10.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
There are currently 85,774K shares outstanding in the company with a market cap of 3.91 billion. Presently, the company’s annual sales total 37,310 K according to its annual income of -366,250 K. Last quarter, the company’s sales amounted to 35,690 K and its income totaled -37,310 K.
